Should molnupiravir be used for covid-19 outpatient management in individuals at high risk for disease severity? A systematic review and meta-analysis of randomized controlled trials

There is currently no consensus on whether to initiate molnupiravir treatment for all outpatients at high risk of severe SARS-CoV-2 infection. PubMed, Embase and Cochrane databases were systematically searched for studies that allocated COVID-19 high-risk, non-hospitalized patients to molnupiravir o...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian Journal of Pharmaceutical Sciences 2024-08, Vol.60
Main Authors: Authorship, SCIMAGO INSTITUTIONS RANKINGS
Format: Article
Language:English
Subjects:
Clinical trials
Collaboration
COVID-19 vaccines
Diabetes
Drug dosages
Encephalitis
Illnesses
Immunization
Infections
Meta-analysis
Mortality
Respiratory syncytial virus
RNA polymerase
Severe acute respiratory syndrome coronavirus 2
Standard of care
Systematic review
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is currently no consensus on whether to initiate molnupiravir treatment for all outpatients at high risk of severe SARS-CoV-2 infection. PubMed, Embase and Cochrane databases were systematically searched for studies that allocated COVID-19 high-risk, non-hospitalized patients to molnupiravir or a control. We computed risk ratios (RR) for binary endpoints, with 95% confidence intervals (CI), random effects model was used and a p-value
ISSN:1984-8250
2175-9790
DOI:10.1590/s2175-97902024e231030